Clinical Trial Update: LUTATHERA Injection General Use Result Survey

View source ↗

Summary

A completed clinical trial update reports general-use results for Lutathera (lutetium Lu-177 dotatate) injection in somatostatin receptor–positive neuroendocrin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Somatostatin Receptor-positive Neuroendocrine Tumor | Status: COMPLETED